Endothelin-1 urinary excretion, but not endothelin-1 plasma concentration, is increased in renovascular hypertension by Cecioni, Ilaria et al.
Endothelin-1 urinary excretion, but not endothelin-1 
plasma concentration, is increased in renovascular 
hypertension 
ILARIA CEClONI, PIETRO AMEDEO MODESTI, LOREDANA POGGESI, FEDERICA ROCCHI, 
LUIGI REGA, and GIAN GASTONE NERI SERNERI 
FLORENCE, ITALY 
Animal experiments have shown an increase in prepro-endothelin-I (prepro-ET-I) 
mRNA expression in the clipped kidney but none in the aortic and mesenteric arter- 
ies in 2-kidney, I -clip Goldblatt hypertensive rats. The present study was aimed at 
investigating whether plasma and renal endothelin-I (ET-I) systems are differently 
activated in patients with renovascular hypertension (RH). The plasma concentra- 
tion and urinary excretion of ET-I were measured in 5 patients with RH (before and 
after successful renal angioplasty), in 7 patients with essential hypertension (EH), 
and in 8 normotensive control subjects. Immediately before renal angioplasty, plas- 
ma samples for ET-I and plasma renin activity (PRA) measurements were with- 
drawn from the aorta and both renal veins. Unlike the PRA, the plasma ET-I con- 
centration did not significantly differ between the involved and the uninvolved 
sides. The urinary ET-I excretion level (Fig I) was markedly increased in patients 
with RH (30 -+ 4 ng/g urinary creatinine [UC] vs 2.5 -+ 0.2 ng/g UC and 2.6 + 0.5 ng/g 
UC in control subjects and patients with EH, respectively; P < .001), whereas the 
plasma ET-I concentration was normal (0.8 -+ 0.2 pg/mL vs 0.65 +- 0.3 pg/mL and 
0.8 _+ 0.2 pg/mL in control subjects and EH, respectively, not significant). Renal 
angioplasty was followed in all patients by normalization of blood pressure and 
PRA. One week after angioplasty, urinary ET-I decreased to one fourth of baseline 
(8.04 _+ 5.23 ng/g UC, P < .001 vs values before angioplasty and P < .04 vs control 
subjects) and normalized I month thereafter (3.13 _+ 1.62 ng/g UC, not significant 
vs control subjects), whereas plasma ET-I remained steady. The present findings 
clearly indicate that in patients with RH, urinary ET-I excretion is increased, where- 
as plasma ET-I concentration remains normal. Successful percutaneous translumi- 
nal renal angioplasty induced a notable reduction in ETo I urinary excretion, where- 
as it did not affect ET- I plasma concentration. (J Lab Clin Med 1999; 134:386-9 I) 
Abbreviations: ACE = angiotensin-converting enzyme;  EH = essential hypertension; ERPF = 
effective renal p lasma flow; ET-I = endothelin-1; GFR = glomerular filtration rate; PRA = plas- 
ma renin activity; prepro-ET-1 = prepro-endothelin-1; RAS = renin angiotensin system; RH = 
renovascular hypertension; UC = urinary creatinine 
From the Clinica Medica Generale e Cardiologia, University ofFlorence. 
Supported inpart by grants from the Ministero dell'Universita' e della 
Ricerca Scientifica e Tecnologica. 
Presented in part at the Sixty-ninth Scientific Sessions ofthe Ameri- 
can Heart Association, New Orleans, LA, November 10-13, 1996, 
and published inabstract form (Circulation 1996;94[suppl 1]:1-144). 
Submitted for publication December 14, 1998; revision submitted 
April 19, 1999; accepted April 29, 1999. 
Reprint requests: Pietro Amedeo Modesti, MD, PhD, Clinica Med- 
ica Generale e Cardiologia, University of Florence, Viale Morgagni 
85, 50134 Florence, Italy. 
Copyright © 1999 by Mosby, Inc. 
0022-2143/99 $8.00 + 0 5/1/99923 
E ndothelin-1 is a vasoconstrictor peptide that is 
also present in urine, where its concentration is 
about 10 times higher than that in plasma. 1Uri- 
nary ET-1 appears to be mainly derived from the 
amount of ET-1 locally produced in the kidney2, 3 by 
different cell types, including peritubular vascular 
endothelial cells and tubular epithelial cells. 4 
Experimental evidence seems to indicate that ET-1 
acts in the kidney as a local autocrine paracrine factor 
rather than as a circulating hormone for the following 
reasons: (1) ET-1 secretion by endothelial cells in cul- 
ture is polar, being directed toward the basolateral 
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rather than the luminal side; 5 (2) ET-1 and the mRNA of 
its precursor, the prepro-ET-1, are present in high con- 
centrations in endothelial cells and in the inner medullary 
collecting ducts in both tubules and the interstitium4,6-s; 
(3) in the absence of changes in circulating ET-1, 
changes occur in the renal synthesis and urinary excre- 
tion of ET-1 in close relationship to fluid handling. 9,1° 
Renal ET-1 production is affected by volemic 
changes because it is inhibited by the increased kidney 
blood perfusion during acute volume expansion 11 and 
conversely is enhanced by prolonged standing 9 or blood 
volume contraction, 12both of which reduce renal blood 
flow. Renal ET-1 in turn appears to contribute to renal 
fluid handling by causing antinatriuresis and an 
increase in free water clearance.lO, 13Animal experi- 
ments showed an increased renal expression of mRNA 
for prepro-ET-114 and normal vascular expression of 
the ET-1 gene in two-kidney, one-clip Goldblatt hyper- 
tensive rats.15 In renovascular hypertensive patients, 
either normal 16-18 or increased 19 plasma ET-1 concen- 
tration has been reported, but no study has assessed uri- 
nary ET-1. The aim of the present study was therefore 
to investigate whether plasma and renal ET-1 systems 
are differently activated in patients with RH. 
METHODS 
Subjects investigated. Five patients with atherosclerotic 
RH, confirmed by renal angiography with renal vein PRA 
sampling, and 7 patients with EH were investigated. Eight 
healthy normotensive subjects erved as control subjects. 
Informed consent was obtained from all of the subjects inves- 
tigated. The clinical and echocardiographic characteristics of 
the subjects investigated are shown in Table I. Antihyperten- 
sive medications, except clonidine, were gradually withdrawn 
before the study so that none of the patients used any other 
antihypertensive drugs for at least 2 weeks before experimen- 
tal procedures. Subjects were excluded from entry if they had 
experienced myocardial infarction or any cerebrovascular acci- 
dent within the previous 6months or if there was any evidence 
in the history, physical examinations, or routine laboratory 
evaluations of other secondary forms of hypertension. Sub- 
jects were also excluded if they had diabetes mellitus, kidney 
failure, abnormal liver function tests, heart failure, significant 
valvular heart disease, or atrial fibrillation. RH was diagnosed 
or excluded on the basis of radionuclide scintigraphy with 
technetium 99m-labeled diethylenetriamine-pentaacetic id 
to assess the GFR and iodine 131-labeled hippurate to evalu- 
ate ERPK 20 renal arteriography, and selective PRA assay in 
the renal veins. Fifty percent or more luminal narrowing of a 
main renal artery with a renal vein PRA ratio of 1.5 or above, 
calculated by dividing the highest renal vein PRA value by the 
lowest, was considered tobe indicative of RH. 21 
Experimental procedure. All of the subjects with hyper- 
tension were inpatients of our institution. They underwent 24- 
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Fig 1. Daily urinary ET-1 excretion (left panel) and plasma ET-1 con- 
centration (right panel) in patients with RH before (0) and 1 and 4 weeks 
after enal angioplasty. The shaded area indicates 95% confidence lim- 
its for healthy controls. *P < .05, **P < .0001 vs control subjects. 
hour blood pressure monitoring, assay of peripheral PRA in 
the supine and standing positions, radionuclide scintigraphy 
for measurement of GFR and ERPF, renal arteriography, and 
assay of selective PRA and ET-1 concentration i  the renal 
veins. All procedures were performed in the morning, with 
the patients upine and fasting after at least 1 week of nor- 
mal sodium diet (108 mEq Na/d). The day before renal 
catheterization, 24-hour urine samples were collected and 
diuresis, urinary ET-1, aldosterone, creatinine, sodium excre- 
tion, and free water clearance were measured. At the same 
time, venous amples were obtained for measurement of plas- 
ma ET-1, sodium, and creatinine. In subjects with a diagno- 
sis of RH, renal angioplasty was performed, and all investi- 
gations, except renal catetherization, were repeated 1week 
and 1 month thereafter. 
ET-1 assay. Blood and urine samples for ET-1 measurement 
were collected and extracted as previously described. 11The 
extraction recovery rate, calculated by the addition of four 
concentrations of cold ET-1 (Peninsula Lab Inc, Belmont, 
CA) was 70% ± 9% for plasma nd 90% _+ 5% for urine. ET- 
1 was assayed by radioimmunoassay with polyclonal specif- 
ic rabbit antibody (Peninsula) at a final dilution of 1:24,000 
for urine and 1:72,000 for plasma.ll Antibody cross-reactivi- 
ties were 7% with ET-2 (human), 7% with ET-3 (rat, human), 
and 17% with big-endothelin (human). There was no cross- 
reactivity with big-endothelin 22-38 (human). Intra- and inter- 
assay variability values averaged 4% and 10% for plasma nd 
3% and 12% for urine, respectively. The minimum detectable 
concentration was 0.1 pg/tube. Results were expressed as 
picograms per milliliter for plasma nd nanograms per gram 
of UC for urine. 
Blood samples for PRA were collected in ice-cold tubes, 
immediately centrifuged, and stored at -20°C. PRA was then 
measured by radioimmunoassay and results were expressed 
as the hourly rate of angiotensin I generation ( g/mL/h)(sen- 
sitivity of 50 pg/tube angiotensin I, intra-assay and inter-assay 
variability coefficients 6% and 10%, respectively). 
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Tab le  I. Cl inical and  echocard iograph ic  character ist ics  of  invest igated subjects 
Renovascular hypertension 
Essential Before I Week after I Month after 
Controls hypertension angioplasty angioplasty angloplasty 
Age (y) 
Sex (M/F) 















LVDDI (cm/m 2) 
LVMI (g/m 2) 
61 ±6 58±7 60±5 
6/2 6/1 4/1 
123 ± 7 164 ± 15 197 ± 8 
118 ± 4 160 ± 10 183 ± 10 
120 ± 5 166 ± 8 186 ± 10 












76±4 101±8 104±5 81±4 73±4 
75±5 96±6 99±4 78±3 77±1 
78±4 98±8 103±6 81±3 83±3 
71±6 94±7 95±2 72±3 70±1 
64±4 59±5 62±9 
8.9±1.0 11.4±1.4 11.3±1.2 
9.2±0.8 11.1±1.5 11.3±1.2 
2.7±0.1 2.7±0.3 3.0±0.2 





LVEF, Left ventricular ejection fraction; S, septum; PW, posterior wall; LVDDI, left ventricular end-diastolic dimension index; LVMI, left ventricu- 
lar mass index. 
Statistical analysis. If not otherwise indicated, data are pre- 
sented as mean _+ SD. Comparisons of a single observation 
between groups (control subjects, patients with EH, and 
patients with RH) were performed with analysis of variance. 
All statistical analyses were performed with BMDP statisti- 
cal software (BMDP Statistical Software, Los Angeles, CA). 
RESULTS 
The clinical and echocardiographic characteristics of 
the subjects investigated are given in Table I. In patients 
with EH, plasma ET-1 concentration i  the antecubital 
vein (0.79 _ 0.20 pg/mL) was non-significantly differ- 
ent from that in control subjects (0.65 _+ 0.30 pg/mL). 
In patients with EH, the ET-1 concentration i blood 
from renal veins did not significantly differ between the 
two sides (on average 0.64 _+ 0.23 pg/mL, with a mean 
ET-1 ratio between the two kidneys of 1.00 _ 0.10 
pg/mL and a mean ET-1 aorta-renal vein gradient of 
0.002 _+ 0.18 pg/mL). Urinary ET-1 excretion was non- 
significantly different from that in control subjects (2.62 
_ 0.53 ng/g UC vs 2.46 ___ 0.18 ng/g UC, not significant). 
Patients with RH had a significant stenosis of one 
main renal artery at angiography (85% _+ 8%). The mean 
size of the affected kidney (104 _+ 11 mm) was not sig- 
nificantly lower than the unaffected one (122 _+ 4 mm). 
ERPF and GFR were significantly reduced in the affect- 
ed kidney in comparison with the unaffected one (106 
_+ 50 mL/min/1.73 m 2 vs 263 _+ 80 mL/min/1.73 m 2 and 
27 +_ 9 mL/min/1.73 m e vs 51 _ 16 mL/min/1.73 m 2, 
respectively, P < .05 for both). PRA values were higher 
in renal veins of the affected kidney (5.3 _ 1.4 ng/mL/h) 
than in those of the unaffected kidney (1.8 _+ 0.2 
ng/mL/h, P < .001), with a renal vein PRA ratio between 
the involved and the uninvolved side of 2.94 _+ 0.89. 
Plasma ET-1 concentration i the antecubital vein 
(0.80 +_ 0.29 pg/mL) was non-significantly different from 
that in control subjects and in patients with EH (not sig- 
nificant for both). ET-1 concentration was similar in the 
renal veins of the involved (0.55 _+ 0.27 pg/mL) and unin- 
volved kidneys (0.57 _+ 0.27 pg/mL, not significant 
between the two sides), with an average ratio of 1.10 _+ 
0.21, and was non-significantly different in comparison 
with patients with EH (not significant). Conversely, in 
patients with RH the daily urinary ET-1 excretion (30.02 
_+ 3.52 ng/g UC) was markedly higher than that in con- 
trol subjects (2.46 _ 0.18 ng/g UC, P < .0001) and in 
patients with EH (2.62 _+ 0.53 ng/g UC, P < .0001). 
Renal angioplasty was technically successful, and 
after 1 week, 24-hour urinary aldosterone and blood 
pressure were normalized. PRA in the supine and 
upright postures was significantly reduced (from 4.3 _ 
2.0 ng/mL/h and 13.4 _+ 8.2 ng/mL/h at baseline to 0.6 
_+ 0.4 ng/mL/h and 1.8 _ 0.4 ng/mL/h 1 week after 
angioplasty). After 1 month, the ERPF and GFR values 
in the affected kidney were significantly increased (180 
_+ 41 mL/min/l.73 m 2 and 40 _+ 8 mL/min/1.73 m 2, 
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respectively, P < .05 vs baseline), with a mild reduc- 
tion in values of the unaffected side (200 _+ 48 
mL/min/1.73 m 2 and 42 + 7 mL/min/1.73 m2). 
One week after angioplasty, urinary ET-1 excretion 
was reduced to one fourth (8.04 _ 4.68 ng/g UC, P < 
.001 vs baseline, and P < .05 vs control subjects) and 
normalized 1month thereafter (3.13 + 1.45 ng/g UC, not 
significant vs control subjects). The reduction in urinary 
ET-1 excretion 1week after angioplasty was paralleled 
in all subjects by an increase in 24-hour urinary volume 
(from 1587 _+ 502 mL to 1975 _ 466 mL, P < .05) and 
sodium excretion (from 110 + 5 mEq/24 h to 156 + 5 
mEq/24 h, P < .05). Free water clearance decreased from 
-0.54 + 0.23 mL/min to -0.85 _ 0.23 mL/min (P < .05), 
and fractional sodium excretion increased from 0.69% _+ 
0.20% to 1.34% _ 0.26% (P < .05). 
DISCUSSION 
The present results showed that urinary ET-1 excre- 
tion, but not plasma ET-1 concentration, was increased 
in patients with RH and was restored to normal values 
after successful renal angioplasty. 
Previous studies have shown that severe renal 
ischemia, after abdominal aortic cross-clamping proxi- 
mal to the renal arteries in dogs, 22 or total renal pedicle 
occlusion in rats, 23 increased renal tissue ET-1 content. 
Similarly, renal hypoperfusion i  a two-kidney, one-clip 
rat model caused a 2-fold to 3-fold increase in the ET-1 
mRNA content in the clipped kidney. 14 Under these con- 
ditions a powerful activation of the RAS occurs, and 
angiotensin II was in fact reported to enhance the ET-1 
synthesis in cultured endothelial cells. 24-27 However, the 
inhibition of ACE with ramipril (7.5 mg/kg daily) halved 
but did not normalize ET- 1 mRNA in the clipped rat kid- 
ney, thus suggesting that ET-1 synthesis is only partial- 
ly controlled by RAS. 14 Human studies also showed that 
ACE inhibition only partially reduced (by about 30%) 
the increased ET-1 renal production in healthy subjects 
during standing 9 or a low sodium diet. 10 The present 
study does not allow us to speculate on the net effect of 
angiotensin II, because we did not administer ACE 
inhibitors to our renovascular hypertensive patients. Fur- 
thermore, increased angiotensin II levels in the circula- 
tion were not found to be correlated with increased 
expression of mRNA for prepro-ET-1 in the aorta and 
mesenteric artery of two-kidney, one-clip hypertensive 
rats. 15 Thus, additional factors seem to be involved, 
because according to the present findings, only urinary 
ET-1 excretion is markedly increased in patients with 
RH, with plasma ET-1 concentration being unaffected. 
Normal ET-1 concentrations in plasma were also report- 
ed by other groups, 16-18 but no study has yet investigat- 
ed the pattern of urinary ET-1. Thus, in agreement with 
previous tudies by our group, 11 the factors that enhance 
circulating and renal endothelins seem to be physiologi- 
cally independent. 
Apart from angiotensin II, other stimuli such as 
hypoxia and increased osmolality of the renal medulla, 
caused by the reduced renal blood flow, may be respon- 
sible for the enhanced renal ET-1 production in RH. 
Hypoxia significantly increases ET-1 synthesis in 
endothelial calf 28 and human 29,3° cultured cells and in 
the epithelial cells of isolated rat inner medullary col- 
lecting ducts. 31 Animal studies assessing the effects of 
hyperosmolality b  NaC1 gave conflicting results that 
showed either a decrease 32 or an enhancement 33,34 of 
ET-1 production by the epithelial cells of inner 
medullary collecting ducts. However, in human sub- 
jects, low sodium intake, which is characterized by 
increased osmolality of the renal medulla, was found 
to be associated with increased prepro-ET-1 mRNA 
expression i  the epithelial cells of the inner medullary 
collecting ducts and tubules and urinary ET-1 excre- 
tion, even in the presence of angiotensin II blockade.lO 
The stimulating effect of all these factors (angiotensin 
II, hypoxia, and osmolality) is transient in experimental 
studies, being reversed on removal of the stimulus o that 
the normalization ofurinary ET-1 excretion after success- 
ful renal angioplasty sheds no further light on the patho- 
physiologic mechanism that is responsible for the 
enhanced urinary ET- 1 excretion in renovascular patients. 
The significance of increased renal production of 
ET-1 in patients with renal artery stenosis is only a 
speculation, because the functional role of endothelin 
in the the kidney is still unclear. In vitro experiments 
showed that ET-1 inhibits sodium reabsorption in 
epithelial cells of the collecting ducts. 35,36 However, 
the physiologic response to ET-1 in vivo seems to be 
more complex. Clavell et al, 37 using selective ETA and 
ETB antagonists, elegantly showed in dogs that the 
natriuretic effect of ET-1 at the level of epithelial cells 
became vident only when ETA vasoconstrictor recep- 
tors were selectively blocked. Thus the natriuretic effect 
seems to be mediated by ETB receptor stimulation, 
whereas ETA receptor subtype stimulation seems to 
cause anti-natriuresis. In human subjects, low-dose (1 
ng/kg/min) ET-1 infusion caused sodium retention, 
with a fall in the fractional excretion of lithium, in the 
absence of any significant changes in renal blood 
flow. 38 Furthermore, in human subjects an increased 
prepro-ET-1 mRNA expression i  the endothelial cells 
of the post-glomerular vascular capillary network, cir- 
cumventing the proximal and distal tubules and vasa 
recta, was associated with enhanced sodium retention.lO 
Therefore renal ET-1 in human subjects eems to cause 
sodium retention, l°, 13 so that its activation in the steno- 
sis of the renal artery could contribute to the blood pres- 
sure increase. 
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Although urinary ET-1 excretion was increased in all 
patients with RH as compared with control  subjects, 
the number of  patients investigated in the present study 
is too low for us to conclude that increased urinary ET- 
1 excretion may be a marker for the diagnosis of  RH. 
In conclusion,  the present f indings indicate that (1) 
RH is associated with increased urinary ET-1 excretion; 
(2) RAS activation does not cause an increase in plas- 
ma ET-1 concentrat ion;  (3) successful  percutaneous 
transluminal renal angioplasty induces a notable reduc- 
tion in ET-1 urinary excret ion,  whereas it does not 
affect ET-1 plasma concentration. 
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